What should I do if I develop drug resistance after taking Necitumumab?

The U.S. Food and Drug Administration (FDA)approved the EGFR antagonist and IgG1 monoclonal antibody Necitumumab in combination with gemcitabine and cisplatin, providing a new first-line treatment option for patients with metastatic squamous non-small cell lung cancer. Patients with advanced squamous non-small cell lung cancer who received nexituzumab in combination with gemcitabine and cisplatin had significant improvements in overall survival and progression-free survival compared with patients who received gemcitabine and cisplatin alone.

Studies have shown that nexituzumab plus platinum-based chemotherapy was associated with higher rates of rash, venous thromboembolism, eye disease, hypomagnesemia, and dose discontinuation related to total adverse events (AEs) than platinum-based chemotherapy alone. If drug resistance develops after taking Nexituzumab, the doctor may re-evaluate your condition, confirm whether there are other treatment options, and change treatment options according to the specific situation of drug resistance: such as radiotherapy, chemotherapy, immunotherapy, etc., to increase the therapeutic effect. If there are no other effective treatment options, your doctor may recommend that you participate in a clinical trial to try a new drug or treatment.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.